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Jonathan M.K. Bogaerts, MD,* Jacobijn Gussekloo, PhD,*‡ Simon P. Mooijaart, PhD,‡
Sven Streit, PhD,† Rosalinde K.E. Poortvliet, PhD,* and Yvonne M. Drewes, PhD‡
OBJECTIVES: As a person’s age increases and his/her
health status declines, new challenges arise that may lead
physicians to consider deprescribing statins. We aimed to
provide insight into recommendations available in interna-
tional cardiovascular disease prevention guidelines regard-
ing discontinuation of statin treatment applicable to older
adults.
DESIGN: We systematically searched PubMed, EMBASE,
EMCARE, and the websites of guideline development orga-
nizations and online guideline repositories for cardiovascu-
lar disease prevention guidelines aimed at the general
population. We selected all guidelines with recommenda-
tions (instructions and suggestions) on discontinuation of
statin treatment applicable to older adults, published
between January 2009 and April 2019. In addition, we per-
formed a synthesis of information from all other recommen-
dations for older adults regarding statin treatment.
Methodological quality of the included guidelines was
appraised using the appraisal of guidelines for research &
evaluation II (AGREE II) instrument.
RESULTS: Eighteen international guidelines for cardiovascu-
lar disease prevention in the general adult population provided
recommendations for statin discontinuation that were applica-
ble to older adults. We identiﬁed three groups of instructions
for statin discontinuation related to statin intolerance, and none
was speciﬁcally aimed at older adults. Three guidelines also
included suggestions to consider statin discontinuation in
patients with poor health status. Of the 18 guidelines included,
16 made recommendations regarding statin treatment in older
adults, although details on how to implement these recommen-
dations in practice were not provided.
CONCLUSION: Current international cardiovascular dis-
ease prevention guidelines provide little speciﬁc guidance
for physicians who are considering statin discontinuation in
older adults in the context of declining health status and
short life expectancy. J Am Geriatr Soc 00:1-9, 2019.
Key words: cardiovascular diseases; clinical decision
making; drug therapy; hydroxymethylglutaryl-CoA
reductase inhibitors; prevention
Up to the age of approximately 75 years, the effectivenessof cardiovascular preventive medication is undisputed
and, together with lifestyle interventions, signiﬁcantly reduces
the impact of cardiovascular disease.1-3 Also, for vital
adults aged 75 to 85 years, there is evidence that the ben-
eﬁts of statins generally outweigh the risks, especially in
secondary prevention.4,5 However, when confronted with
declining health status and the development of complex
health problems, the use of preventive medications with
long-term effects might become of questionable beneﬁt;
on the one hand, treatment priorities shift and life expec-
tancy shortens, while on the other hand, the risks of
adverse effects increase due to pharmacokinetic and
pharmacodynamic changes, polypharmacy, and
multimorbidity,6-9 especially in old age. These risks can
be inﬂuenced positively by decreasing medication pre-
scriptions. In addition, high-quality evidence is not yet
available for either primary or secondary statin-based
prevention in people aged 85 years and older or in those
with complex health problems (as they are currently
excluded from trials).10 In a recent meta-analysis of the
efﬁcacy and safety of statins for primary cardiovascular
disease prevention in older adults, which included data
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from 28 trials, only 8% of all patients were aged older
than 75 years at enrollment.5 As statins are one of the
most commonly used drugs in the older population, with
a prevalence ranging between 18% and 45%,11,12 with
concerns about the beneﬁts, they have been identiﬁed as
possible candidates for deprescribing (the process of
tapering or stopping inappropriate medication) by both
clinicians and patients.10,11,13-19 In a modiﬁed Delphi
approach, physicians, pharmacists, and nurses prioritized
statins in the top three of a list of medication classes
where evidence-based deprescribing guidelines would be
of beneﬁt to clinicians because of concerns about beneﬁt
given the lack of older patients in trials, the lack of
clarity around ongoing indication and when they can be
stopped, as well as an emerging recognition of adverse
effects and overtreatment of low-risk patients.14
Qualitative studies have shown that both physicians
and patients are generally open to statin deprescription in
the case of older adults.19-22 Nevertheless, medications,
including statins, are often continued until death.17,23 It has
been reported that physicians do not feel conﬁdent about
deprescribing cardiovascular preventive medication and sur-
vey studies have found considerable treatment variation in
the advice regarding discontinuation of preventive medica-
tion.22,24,25 A likely contributing factor and an acknowl-
edged barrier to deprescribing medications is the lack of
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ﬂow chart showing the selection process
of the guidelines.CPG: Canadian Clinical Practice Guidelines InfoBase; G-I-N: Guidelines International Network; NGC: National
Guideline Clearinghouse; SIGN Scottish Intercollegiate Guidelines Network (SIGN)
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evidence and clear guidance in clinical practice guide-
lines.10,21,25 Therefore, the primary objective of this system-
atic review was to provide insight into the available
recommendations regarding statin treatment discontinua-
tion in older adults as provided by international guidelines
on cardiovascular disease prevention in the general popula-
tion. To explore the context of recommendations for dis-
continuation applicable to older adults, we additionally
analyzed which other recommendations were formulated
concerning statin treatment in older adults.
METHODS
Search Strategy
Identiﬁcation and Screening of the Records
Following consultation with an experienced health research
librarian, we conducted systematic electronic searches in
PubMed, Emcare, and Embase for references published from
January 1, 2009 (search date April 23, 2019). We combined
Table 1. Characteristics of Guidelines That Include Recommendations for Statin Discontinuation Applicable to Older
Adults (n = 18)
Author Year Country Organization Age, y Excluding Intended users
Allan et al28 2015 Canada TOP NS Primary care clinicians and their
teams
Catapano et al29 2016 Europe ESC, EAS All ages Healthcare professionals
Downs et al30 2015 United States Va/DoD Adults Patients with severe
systolic chronic heart
failure, with end-stage
renal disease, and on
dialysis, or those with a
limited life expectancy
Primary care providers
Fan et al31 2014 United States UMHS 20-79 Patients with familial or
severe dyslipidemias or
chronic kidney disease
NS
Grundy et al32 2018 United States ACC, AHA ≥21 Primary care clinicians, specialists
concerned with ASCVD prevention
Guerrero33 2016 Philippines PHA, PLAS,
PSEM
NS Filipino physicians
Jacobson et al34 2015 United States NLA All ages Clinicians
Jellinger et al35 2017 United States AACE, ACE All ages Endocrinologists
Kinoshita et al36 2018 Japan JAS All ages NS
Last et al37 2011 United States NS Family physicians
Lewis38 2009 United States NS Physicians
Li et al39 2017 Taiwan TSLA NS Healthcare professionals
MoH Malaysia40 2017 Malaysia MoH Malaysia,
NHAM, AM
All ages General practitioners, medical
ofﬁcers, pharmacists, general and
family
physician, cardiologists, and
endocrinologists
MoH Qatar41 2016 Qatar MoH Qatar NS Physicians in both primary/
generalist and secondary/specialist
care settings
NICE42 2014 United Kingdom NICE NS (i.a.) People on renal
replacement therapy
Healthcare professionals
NVDPA43 2012 Australia NVDPA Adults General practitioners, aboriginal
health workers, other primary care
health professionals and
physicians
SIGN44 2017 United Kingdom SIGN All ages People with chronic heart
failure, acute coronary
syndrome, stable angina,
or cardiac arrhythmia
Healthcare professionals, public
health staff, patients, caregivers,
voluntary organizations, policy
makers
Tai et al45 2017 Singapore MoH Singapore All ages All physicians, particularly primary
care physicians
Abbreviations: AACE, American Association of Clinical Endocrinologists; ACC, American College of Cardiology; ACE, American College of Endocrinology;
AHA, America Heart Association; AM, the Academy of Medicine; ASCVD, atherosclerotic cardiovascular disease; EAS, European Atherosclerosis Society;
ESC, European Society of Cardiology; i.a, if applicable; JAS, Japanese Atherosclerosis Society; MoH, Ministry of Health; NHAM, National Heart Associa-
tion of Malaysia; NICE, National Institute for Health and Care Excellence; NLA, National Lipid Association; NS, not speciﬁed; NVDPA, National Vascular
Disease Prevention Alliance; PHA, Philippine Heart Association; PLAS, Philippine Lipid and Atherosclerosis Society; PSEM, Philippine Society of Endocrinol-
ogy, Diabetes, and Metabolism; SIGN, Scottish Intercollegiate Guidelines Network; TOP, Towards Optimized Practice; TSLA, Taiwan Society of Lipids and
Atherosclerosis; UMHS, University of Michigan Health System; Va/DoD, Department of Veterans Affairs and the Department of Defense.
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thesaurus terms and free text to deﬁne “statins,” “cardiovas-
cular diseases,” “cholesterol,” and “lipids” and terms for the
concept “guideline” (Supplementary Text S1 provides the
complete strategies). We additionally searched the follow-
ing websites of guideline development organizations and
guideline repositories: Scottish Intercollegiate Guidelines
Network (SIGN) (http://www.sign.ac.uk/); Guidelines
International Network (G-I-N) (http://www.g-i-n.net/);
National Guideline Clearinghouse (NGC) (https://www.
guideline.gov/); Canadian Clinical Practice Guidelines
Infobase (https://www.cma.ca/En/Pages/clinical-practice-
guidelines.aspx); and UpToDate (https://www.uptodate.
com/contents/search). For the search, we used the same ter-
minology on April 24, 2019, with the exception of the G-I-N
database (access date April 12, 2018) due to inaccessibility
of the G-I-N database from July 2018.
Study Selection
After removal of duplicate records, one reviewer (M.P.)
assessed the initial eligibility of the retrieved studies based
on the title and abstract by checking the following exclusion
criteria: (a) publication is not a guideline; (b) publication is
not about statin treatment; (c) publication does not regard
a general adult population (eg, disease- or population-
speciﬁc guidelines, such as “patients with diabetes” or
“patients with stroke”); guidelines for the general adult
population that also include recommendations for second-
ary prevention were not excluded; (d) publication is an old
version of a more recently published guideline; and (e) full
text is not available in English. When there was any doubt
based on the title, abstract, or publication information to
determine the relevance, the publication was included for
further assessment. Subsequently, two investigators
(M.P. and Y.D.) assessed the full-text publications regard-
ing inclusion and the already above mentioned exclusion
criteria. The inclusion criteria were: (a) cardiovascular dis-
ease prevention guidelines concerning the general
population and (b) published in the last 10 years. Addition-
ally, the two investigators (M.P. and Y.D.) assessed the
availability of recommendations for statin treatment discon-
tinuation for older adults (third inclusion criterion). Guide-
lines without recommendations for statin discontinuation
recommendations or with only recommendations not appli-
cable to older adults (eg, pregnancy and lactation related)
were excluded. During consensus meetings, the investigators
compared their assessments and discussed differences until
consensus was reached.
Quality Assessment
Two investigators (M.P. and C.F.) assessed the methodolog-
ical rigor of each guideline using the AGREE II instru-
ment.26 AGREE II consists of 23 items rated on a 7-point
Likert scale (1 = strongly disagree [item is absent or poorly
written] to 7 = strongly agree [the quality of the item is
exceptional and full criteria articulated in the User Manual
have been met]). AGREE II items are organized into six
quality domains: (a) scope and purpose, (b) stakeholder
involvement, (c) rigor of development, (d) clarity of presen-
tation, (e) applicability, and (f ) editorial independence, with
a 24th item related to overall quality (Supplementary Text
S2 provides more details about the rating process and the
calculation of the scaled domain scores). The intraclass cor-
relation coefﬁcient (ICC) for interrater agreement on the
total number of all ratings was calculated using SPSS, ver-
sion 23.0 (SPSS Inc).
Information Synthesis: Recommendations for
Discontinuation and Other Recommendations for Older
Adults
All recommendations for statin discontinuation applicable to
older adults were summarized into groups with similar content.
We havemade a distinction between recommendations that were
phrased in a directive way (instructions) and recommendations
Table 2. Recommendations for Statin Discontinuation Applicable to Older Adults in 18 International Guidelines
Group
No. of guidelines
with this
recommendation Guidelines
Intolerance Should be discontinued (at least temporarily):
• Muscle symptoms (including rhabdomyolysis) 12 28,29,31-33,35,36,39,40,42,43,45
• Liver toxicity 5 29,30,38,40,45
• Contraindication 2 37,44
Consider discontinuation/might not be appropriate
(to continue)
• Muscle symptoms (including rhabdomyolysis) 3 28,41,44
• Cognitive dysfunction after the start of statins
(to assess reversibility)
1 34
Health status Consider discontinuation:
• Limited life expectancy 3 30-32
• Multimorbidity/increasing comorbidities 3 30-32
• Frailty 1 32
• Functional decline (physical or cognitive) 1 32
• When harm (eg, polypharmacy, adverse drug reactions)
may outweigh beneﬁt
2 30,32
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phrased as suggestions (suggestions). To explore the context of
recommendations for the discontinuation of statins applicable to
older adults, we additionally analyzed the selected guide-
lines for other recommendations and considerations con-
cerning statin treatment in older adults (deﬁned as
recommendations for adults aged ≥75 years or referred to
as “old” or “older” adults/people/patients or “elderly,”
regarding all aspects of treatment). These recommenda-
tions were then synthesized into short statements and sum-
marized into groups with related content. In a
supplementary analysis, we checked whether the content
of the recommendations concerning older adults in the
excluded guidelines matched that mentioned in the
included guidelines.
Registration of Protocol
The review protocol was registered in PROSPERO
(CRD42018116424).
Table 3. Distribution of General Recommendations for Statin Treatment for Older Adults in the 18 Included
Guidelines
Recommendation
Limited to initiating
therapy
no. of guidelines
Guideline
reference
Regarding
therapy in general
no. of Guidelines Guideline reference
Drug safety related Extravigilance, beware of
adverse effects
2 31,45 5 29,30,32,36,40
(Consider) a lower (start or
target) dose
3 29,35,40 4 31,32,34,45
Take into account drug-drug
interactions
1 45 3 29,32,34
Take into account
polypharmacy
2 41,42 6 29,30,32,34,36,45
Take into account
pharmacokinetic/dynamic
changes
1 40 4 29,32,36,45
Take into account risks and
beneﬁts
5 32,41-43,45 6 28,30,32,34,37,38
Health related Take into account:
• life expectancy 5 36,41,42,44,45 6 28,30,32,36,37,43
• comorbidities/multimorbidity 5 31,40-43 6 29,32,36,45,47,48
• quality of life 3 44,45
• frailty 2 41,42 4 28,32,34,36
• health status - - 1 28
• potential beneﬁts from
lifestyle modiﬁcations
2 41,42
• costs 1 34
• variability in physical
functions
1 36
• cognitive decline 1 32
• vital prognosis 1 36
Preference and
judgment
Take into account (informed)
patient preference
4 41-43,45 4 32,34,37,38
Shared decision making 3 28,42,43 4 30,32,34,41
Take into account: priorities of
care
1 31 - -
Start or continue • Continue treatment for those
aged >75 y if well tolerated
5 28,31,32,40,45
• Reconsider the
recommendation to treat
periodically
2 32,40
• Screening for dyslipidemia for
those aged >75 y or in patients
with limited life expectancy:
may not be appropriate/is
recommended to be stopped
2 28,31
• For secondary prevention,
treatment with statins is
recommended for older adults
in the same way as for younger
patients
1 29
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RESULTS
A total of 9502 records were identiﬁed by database
searching, 3368 of which were duplicate records. Of the
6134 remaining records, 6060 were found to be irrelevant
(not guidelines or of different topics) based on title or
abstract. We identiﬁed an additional 60 records from other
websites from which we excluded 37 as duplicate records.
These searches ﬁnally yielded 97 potentially relevant records
to be screened for eligibility, of which 64 were excluded for
reasons described in Figure 1 (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses ﬂow chart).27 Dur-
ing the consensus meetings, the investigators agreed that
summary documents, which provide guidelines without the
full scientiﬁc background, were also to be excluded.
The remaining 33 records were guidelines containing
recommendations for statin treatment in the general adult
population that originated from 11 different countries/
regions (Australia, Canada, Europe, Japan, Malaysia, Phil-
ippines, Singapore, Taiwan, United Kingdom, United States,
and Qatar). Of these 33 guidelines, 15 (45%) did not
include recommendations regarding statin discontinuation
applicable to older adults at all, not even discontinuation
for reasons such as contraindications, and were, therefore,
excluded from the study.
The remaining 18 international guidelines were
included in this study, and the primary characteristics of
these guidelines are described in Table 1. With the excep-
tion of one guideline,31 none of the guidelines included an
upper age limit in the description of the population cov-
ered. Four guidelines stated that recommendations for cer-
tain populations, such as people with limited life
expectancy, were not included.30,31,42,44 Sixteen guidelines
(excluding two19,46) included recommendations for both
primary and secondary prevention. One guideline46 did
not include a quality grading system for assessment of the
level of evidence supporting the recommendations. All
guidelines included one or more expert or consensus-based
recommendations.
Information Synthesis
Recommendations for Statin Discontinuation Applicable
to Older Adults
We identiﬁed two groups of recommendations regarding
(at least temporary) statin discontinuation that were also
applicable to older adults, speciﬁcally statin intolerance and
health status. An overview of statin discontinuation recom-
mendations can be found in Table 2. Recommendations
regarding statin intolerance were present in all 18 guidelines
included in this study and related to muscle symptoms (includ-
ing rhabdomyolysis), elevation of transaminase levels, and the
presence of contraindications. In 16 of the 18 guidelines, these
recommendations were formulated in directive words
(“should” or “have to be” discontinued) or named as a con-
traindication (instructions). None of the guidelines reported
instructions for statin discontinuation that were exclusively
aiming at older adults. Three guidelines30-32 included sugges-
tions for statin discontinuation in patients with (development
of) poor health status, such as patients with functional decline
during treatment or a limited life expectancy (see category
“health status” in Table 2). These suggestions used phrases
such as “it might be reasonable to consider statin discontinua-
tion” in patients with short life expectancy, multimorbidity or
increasing comorbidities, frailty, or functional decline, or
when harm outweighs beneﬁt. One guideline recommended
that statins should only be considered in primary prevention
Table 4. Scaled Domain Scores of AGREE II Instrument for the Included Guidelines
Guideline
Scope and
purpose
Stakeholder
involvement
Rigor of
development
Clarity of
presentation Applicability
Editorial
independence Overall
Allan et al28 89 78 59 83 56 50 50
Catapano et al29 83 50 60 94 83 54 83
Downs et al30 86 78 77 94 54 58 83
Fan et al31 78 25 27 83 27 29 42
Grundy et al32 89 78 78 94 58 71 83
Guerrero33 83 31 65 78 42 8 58
Jacobson et al34 83 72 55 86 54 50 67
Jellinger et al35 94 64 75 89 67 71 75
Kinoshita36 43 17 28 48 18 33 33
Last et al37 31 8 41 75 13 13 17
Lewis38 33 8 4 33 13 13 17
Li et al39 50 44 30 78 15 17 33
MoH Malaysia40 97 61 78 81 63 71 67
MoH Qatar41 44 39 21 72 23 63 25
NICE42 92 78 81 86 88 67 92
NVDPA43 89 94 81 94 92 96 92
SIGN44 94 94 94 100 94 92 100
Tai et al45 44 50 40 94 38 25 33
Note: Percentage of maximum scaled domain score, based on two appraisers. For details on the calculation, see Supplementary Text S2.
Abbreviations: MoH, Ministry of Health; NICE, National Institute for Health and Care Excellence; NVDPA, National Vascular Disease Prevention Alliance;
SIGN, Scottish Intercollegiate Guidelines Network.
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in cases with at least 3 or more years of life expectancy.36
However, the guideline did not explicitly recommend statin
discontinuation in those already on statin treatment. An over-
view of recommendations concerning statin discontinuation is
provided in Supplementary Table S3.
Other Recommendations Regarding Statin Treatment in
Older Adults
The context of recommendations on statin discontinuation
applicable to older adults was further explored by analyzing
which other recommendations were formulated in relation to
statin treatment in older adults. We found that 16 of the
18 guidelines included at least one recommendation con-
cerning statin treatment in older adults. Across guidelines, the
lower age limit deﬁning older adults ranged from 65 years
and older to 85 years and older or was not provided. We dif-
ferentiated four groups of recommendations regarding statin
treatment in older adults, including: (a) recommendations
related to drug safety, including the need for extra vigilance
for adverse effects, a lower (start) dose, or a higher low-
density lipoprotein target (n = 15 guidelines); (b) health-
related recommendations, including recommendations to take
into account factors such as comorbidities or frailty (n = 15
guidelines); (c) recommendations related to taking patient
preference into account and/or to base treatment decisions on
clinical judgment (n = 11 guidelines); and (d) recommenda-
tions regarding starting and continuing statin treatment (n = 7
guidelines). Details on how these recommendations should be
implemented in practice were not provided. In Table 3, the
distribution of these recommendations (summarized into short
statements) in the guidelines is described. The relevant full rec-
ommendations can be found in Supplementary Table S2.
Quality Assessment
Table 4 summarizes the quality appraisals by scaled AGREE
domain scores. The domains clarity of presentation and
scope and purpose were assigned the highest median scores
of 84.5% (range = 33%-100%) and 83% (range = 31%-
97%), respectively. The domains applicability and editorial
independence were assigned the lowest median scores of
54% (range = 13%-94%) and 52% (range = 8%-96%),
respectively, making them the least well-addressed domains.
The widest range of scores observed was in the domain rigor
of development (range = 4%-94%; median = 62.5%). On
overall assessment, 11 guidelines scored 50% or greater and
were considered to be of moderate or good quality. The
overall ICC was 0.90 (95% conﬁdence interval = 0.89-0.92),
indicating excellent interrater agreement.47
Visual inspection of the data did not show a relation
between the overall quality of the guidelines and number of
recommendations concerning older adults.
Supplementary Analyses
The recommendations for statin treatment in older adults,
provided by the 15 excluded guidelines, were of similar
content compared to those discussed in this review, in para-
graph “Other Recommendations Regarding Statin Treat-
ment.” Supplementary Table S3 shows an overview of the
guidelines included in the supplementary analysis.
DISCUSSION
In this systematic review of international guidelines for car-
diovascular disease prevention in the general population, we
searched for recommendations concerning statin discontinua-
tion applicable to older adults. We found that 18 (55%) of
the 33 eligible guidelines provided one or more recommenda-
tions for discontinuation of statin treatment. Remarkably,
the other 15 guidelines (45%) did not include any recom-
mendations regarding statin discontinuation applicable to
older adults, not even discontinuation for reasons such as
contraindications. All the 18 included guidelines provided
recommendations related to statin intolerance; however,
none of these was exclusively for older adults. Sixteen guide-
lines contained instructions and three guidelines provided
recommendations formulated as suggestions to consider
statin discontinuation in (older) patients with poor health
status. In addition, 16 of the included guidelines also pro-
vided other recommendations for statin treatment in older
adults. Safety considerations were the most common recom-
mendations, mostly formulated in general terms.
In a systematic review of guidelines and recommenda-
tions concerning primary cardiovascular disease prevention
for older adults (search dates between April and December
2013), Jansen and colleagues noted that none of the
included guidelines considered discontinuation of medica-
tion in older adults.48 We noticed that some progress has
been made since 2013. We found three guidelines that
reported at least some recommendations regarding poor
health in the context of statin discontinuation.30-32 The lat-
ter were not exclusive to but were at least more prominent
in older adults. Furthermore, the most recently updated
guideline included in our study, the 2018 American College
of Cardiology/American Heart Association (ACC/AHA)
guideline on management of blood cholesterol, is the ﬁrst
guideline to include an extensive discussion on statin dis-
continuation and age-related complexities in the preventive
treatment of older adults.32 It was unique in using the terms
“deprescribing”, “frailty,” and “functional decline” in the
context of statin discontinuation. However, in our view, the
recommendations regarding statin discontinuation in this
guideline were still formulated as suggestions (“it may be
reasonable to”). Although factors are mentioned in the
guideline that limit the potential beneﬁts of statin treatment
in older adults, such as frailty and functional decline, actu-
ally, these factors still do not have a clear circumscription.
Therefore, it remains the physician’s personal judgment to
interpret to what extent the recommendations are applica-
ble on an individual patient.
Our ﬁndings likely reﬂect the lack of high-quality evi-
dence, including functional aspects and frailty, derived from
well-designed statin treatment randomized controlled trials
in older people, as well as the scarcity of trials focused on
deprescribing.46,49 One guideline reported a search for evi-
dence supporting discontinuation of statin treatment in peo-
ple aged 85 years and older and found only one eligible
study.17,44 However, the lack of high-level evidence cannot
fully account for our ﬁndings, since previous research has
shown that many recommendations in international cardio-
vascular disease prevention guidelines (up to 48%) are
based on low-level evidence.50 Furthermore, most of the
guidelines in our study included recommendations based on
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low-level evidence, including expert opinion. Other factors,
such as a lack of awareness among guideline developers,
potential conﬂicts of interest, and the absence of a dep-
rescribing tradition, might explain the scarcity of deprescribing
recommendations in current disease-centered guidelines.50 In
line with this argument, higher methodological quality scores
measured with the AGREE II tool did generally not coincide
with more recommendations for older adults.
Strengths and Limitations
The strengths of this study include a comprehensive system-
atic search strategy and the use of a validated overall meth-
odological quality appraisal (AGREE II tool) of the included
clinical practice guidelines.26 Also, this is the ﬁrst study that
provides an overview of recommendations for statin discon-
tinuation. One of the limitations of this study was the exclu-
sion of guidelines in languages other than English. We were
aware of at least two non–English-language guidelines
(in Norwegian and Dutch) that provide additional guidance
on when to cease statin treatment in older adults, but they
were not included in this review.51,52 Nevertheless, our
review did include insights from guidelines that originated
from a broad range of geographical regions, including
Australia, Asia, Europe, North America, and the Middle
East. A second limitation may have been the summary of dis-
continuation recommendations into short statements through
which some information was lost. To counteract this, we
include an overview of all recommendations used in the
information synthesis (Supplementary Tables S1 and S2).
Conclusion and Future Directions
Although clinically relevant, the subject of statin discontinua-
tion in older adults gets little attention in current interna-
tional cardiovascular prevention guidelines, resulting in a
lack of clear guidance for physicians reconsidering statin
treatment in older adults with complex health problems. In
this population, physicians will have to decide to continue or
discontinue statins based on personal judgment, since evi-
dence concerning the optimal duration of statin treatment in
older frail adults or adults with multimorbidity is currently
lacking.46,49,50,53 Grants to develop randomized trials on
deprescribing in older adults will probably result in more evi-
dence for deprescribing. Until higher-level evidence becomes
available, we suggest that new guidelines strive to combine
available evidence with expert opinion and consensus tech-
niques, to accommodate the need among physicians for more
detailed recommendations regarding the implementation of
deprescription of statins in practice. Issues, such as declining
health status and short life expectancy, can already be dis-
cussed in guidelines as considerations for deprescription.
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